Thus, targeting metabolic intermediates and enzymes such as hexokinase, PFK-1, ME2, LDH-A, MUC-1, MUC-13, FASN, GOT1, GLS, GLUD1, BCAT2, FASN, ASNS, alanine transaminase, and transporters, including SLC1A4 and SLC38A2, might serve as a fruitful strategy to attenuate tumor growth and enhance therapeutic outcome. This evidence concerns the gene ME2 and neoplasm.